This analysis is, to the best of our knowledge, the largest and latest meta-analysis focusing on pT1a-bN0M0 breast cancer patients for the prognostic profiles of various intrinsic subtypes and survival benefits of HER2-positive women receiving adjuvant trastuzumab. The gene discussed is ERBB2; the disease is breast cancer.